...
首页> 外文期刊>Chinese Medicine >Jowiseungki decoction affects diabetic nephropathy in mice through renal injury inhibition as evidenced by network pharmacology and gut microbiota analyses
【24h】

Jowiseungki decoction affects diabetic nephropathy in mice through renal injury inhibition as evidenced by network pharmacology and gut microbiota analyses

机译:Jowiseungki汤剂通过肾脏损伤抑制,通过网络药理学和肠道微生物群分析证明,影响小鼠的糖尿病肾病

获取原文

摘要

Jowiseungki decoction (JSD) is a prescription commonly used for the treatment of diabetic complications or diabetic nephropathy (DN) in traditional medicine clinics. However, the underlying therapeutic mechanisms of JSD are still unclear. Streptozotocin (STZ)-induced DN mice were administered 100 and 500?mg/kg JSD for 4?weeks, and the therapeutic mechanisms and targets of JSD were analyzed by network pharmacology and gut microbiota analyses. JSD significantly decreased the increase in food and water intake, urine volume, fasting blood glucose, serum glucose and triglyceride levels, and urinary albumin excretion. JSD administration significantly increased the decrease in insulin secretion and creatinine clearance and reduced the structural damage to the kidney tissues. Moreover, JSD administration significantly inhibited the expression of protein kinase C-alpha (PKC-α), transforming growth factor beta-1 (TGF-β1), α-smooth muscle actin (α-SMA), nuclear factor-κB (NF-κB), inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) in the kidney tissues of DN mice, while it significantly increased the phosphorylation of insulin receptor substrate 1 (IRS-1), phosphatidylinositol-3-kinase (PI3K), and protein kinase B (Akt). In the network pharmacological analysis, JSD obviously influenced phosphatase binding, protein serine/threonine kinase, and mitogen-activated protein kinase (MAPK)-related signaling pathways. Our data suggest that JSD can improve symptoms in STZ-induced DN mice through the inhibition of kidney dysfunction, in particular, by regulating the PKCα/PI3K/Akt and NF-κB/α-SMA signaling pathways. Gut microbiota analysis can help to discover the pharmaco-mechanisms of the influence of JSD on bacterial diversity and flora structures in DN. JSD can improve the symptoms of DN, and the underlying mechanism of this effect is renal protection through the inhibition of fibrosis and inflammation. JSD can also change bacterial diversity and community structures in DN.
机译:Jowiseungki汤剂(JSD)是一种常用于治疗传统医学诊所糖尿病并发症或糖尿病肾病(DN)的处方。然而,JSD的潜在治疗机制仍然不清楚。施用串脲佐菌素(STZ)诱导的DN小鼠100〜500〜Mg / kg JSD 4?周,通过网络药理学和肠道微生物分析分析JSD的治疗机制和靶标。 JSD显着降低了食品和水摄入量,尿量,空腹血糖,血清葡萄糖和甘油三酯水平的增加,以及尿白蛋白排泄。 JSD管理显着增加了胰岛素分泌和肌酐清除的降低,并降低了对肾组织的结构损伤。此外,JSD管理显着抑制了蛋白激酶C-α(PKC-α)的表达,转化生长因子β-1(TGF-β1),α-平滑肌肌动蛋白(α-SMA),核因子-κB(NF- κB),诱导型一氧化氮合酶(InOS)和DN小鼠肾组织中的环氧氧酶-2(COX-2),同时显着增加了胰岛素受体基质1(IRS-1),磷脂酰肌醇-3-激酶的磷酸化(PI3K)和蛋白激酶B(AKT)。在网络药理学分析中,JSD明显影响了磷酸酶结合,蛋白质丝氨酸/苏氨酸激酶和丝裂原蛋白激酶(MAPK)的信号传导途径。我们的数据表明,JSD通过抑制肾功能紊乱,特别是通过调节PKCα/ PI3K / AKT和NF-κB/α-SMA信号通路,可以通过抑制肾功能障碍来改善STZ诱导的DN小鼠的症状。 Gut Microbiota分析可以帮助发现JSD对DN中细菌多样性和植物群结构影响的药物机制。 JSD可以改善DN的症状,并且这种效果的潜在机制是通过抑制纤维化和炎症的肾脏保护。 JSD还可以在DN中改变细菌多样性和社区结构。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号